查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046330

製藥業生成式人工智慧市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類型、應用、技術、地區和競爭格局分類，2021-2031年

Generative AI in Pharmaceutical Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Application, By Technology By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球製藥業生成式人工智慧市場預計將從 2025 年的 42 億美元成長到 2031 年的 191.3 億美元，複合年成長率為 28.75%。

在這個領域，生成式人工智慧指的是利用先進的機器學習框架，例如深度學習架構和大規模語言模型，自主設計新型分子結構、創建合成患者資料並簡化臨床文件。推動這一市場發展的主要因素是迫切需要縮短藥物研發週期，以及減少研發相關的巨額資本投入。皮斯托亞聯盟在2024年發布的報告也印證了這一趨勢，報告顯示，83%的生命科學專業人士在其研究中使用生成式人工智慧，凸顯了這些技術在提高營運效率和創新能力方面的快速普及。

市場概覽
預測期 2027-2031
市場規模：2025年 42億美元
市場規模：2031年 191.3億美元
複合年成長率：2026-2031年 28.75%
成長最快的細分市場 藥物發現
最大的市場 北美洲

然而，該市場面臨與數據品質和智慧財產權法規合規複雜性相關的重大挑戰。生成模型輸出的準確性高度依賴於無偏且高精度的資料集，但這些資料集在製藥公司內部往往分散或不一致。此外，缺乏全球統一的法規導致資料隱私和版權問題存在不確定性，這可能會阻礙這些工具在安全性和準確性至關重要的關鍵決策情境中的大規模應用。

市場促進因素

透過從頭分子設計加速藥物發現和開發進程的能力是推動生成式人工智慧應用的主要動力。傳統的藥物發現過程耗時漫長，而生成式模型如今能夠以極高的準確率預測分子間相互作用，從而大幅減少識別候選藥物所需的實驗迭代次數。例如，2024年5月，GoogleDeepMind宣布其AlphaFold 3模型在預測蛋白質-配體交互作用的準確率比傳統方法提高了50%。計算準確率的顯著提升使研究人員能夠克服傳統的實驗瓶頸，從而縮短開發週期，並加快新療法從實驗室到臨床試驗的轉化。

此外，成熟的製藥公司與專業的AI技術公司之間的策略合作，透過將生物學專業知識與運算能力結合，正在推動市場成長。大型製藥企業擴大透過高價值的夥伴關係將AI創新外包，以降低技術風險並充分利用其專有的演算法平台。一個典型的例子是Isomorphic Labs與禮來公司於2024年1月達成的一項價值高達17億美元的合作，旨在發現針對多個靶點的小分子療法。這種大規模資本投資的趨勢在整個生態系統中普遍存在，例如Xaira Therapeutics，該公司成立於2024年，投資超過10億美元。該公司正在建立一個用於藥物發現的端到端AI平台，這反映了投資者對產業轉型的堅定信心。

市場挑戰

缺乏高度精確且整合的數據基礎設施是全球製藥業生成式人工智慧市場擴張的主要障礙。生成式模型需要一個龐大、結構化且無偏的資料儲存庫，才能準確預測分子特性並模擬生物反應。然而，製藥資料通常以非結構化格式存儲，或分散在不同的舊有系統中，因此未經大規模處理無法即時應用於機器學習。人工智慧架構的技術要求與企業資料現狀之間的這種差距迫使企業將大量資源投入到資料清洗而非增值創新中，直接阻礙了本應推動市場發展的效率提升。

因此，數據普遍不足造成了瓶頸，阻礙了這些技術的規模化應用。 2024 年 Pistoia Alliance 的一項調查發現，52% 的生命科學專業人士認為低品質、管理不善的資料集是人工智慧應用的主要障礙。當資料完整性受到損害時，產生結果的可靠性就會降低，導致相關人員在將這些工具整合到安全關鍵型工作流程中時猶豫不決。因此，市場難以滿足縮短藥物研發週期的預期，從而有效地抑制了整個產業的成長動能。

市場趨勢

閉合迴路「實驗室在環」系統的整合正在革新藥物研發，它將生成式人工智慧模型與自動化機器人實驗室直接連接起來。在該工作流程中，人工智慧演算法建構分子層面的假設，然後由機器人進行物理檢驗，所得數據立即用於重新訓練模型，從而提高後續的預測準確性。近年來基礎設施的進步清晰地展現了藥物研發透過強大的運算能力實現產業化的趨勢。例如，2024年5月，Recursion公司宣布採用NVIDIA處理器的BioHive-2超級電腦竣工，這是製藥業最快的系統，每周可處理超過200萬個實驗資料集，用於訓練其專有的基礎模型。

同時，合成數據在臨床開發上的應用也在不斷擴展。各公司正利用生成式人工智慧技術創建高度精確的患者“數位雙胞胎”，用於建立合成對照組。這項應用解決了罕見疾病研究中受試者短缺的難題，使試驗能夠在受試者數量大幅減少的情況下保持統計意義。近期的資金籌措趨勢也表明，市場對這種調查方法的支持度很大。例如，2024年2月，Unlearn.AI宣布完成C輪資金籌措，籌集5,000萬美元，用於擴展其「TwinRCT」解決方案。此方案利用生成式模型預測患者的健康結果，從而有效減輕臨床試驗招募受試者的負擔。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：製藥業生成式人工智慧的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（低分子量、高分子量）
    • 按應用領域（臨床試驗研究、藥物發現、研發、其他）
    • 透過科技（深度學習、自然語言處理、查詢方法、情境辨識處理等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美製藥業生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲製藥業生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區製藥業生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲製藥產業生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美製藥業生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球製藥產業生成式人工智慧市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca Plc
  • Nvidia
  • Baidu
  • Johnson & Johnson
  • Sanofi
  • Adaptyv Bio

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20056

The Global Generative AI in Pharmaceutical Market is projected to expand from USD 4.20 Billion in 2025 to USD 19.13 Billion by 2031, registering a CAGR of 28.75%. In this sector, generative AI entails the utilization of sophisticated machine learning frameworks, such as deep learning architectures and large language models, to autonomously design novel molecular structures, create synthetic patient data, and streamline clinical documentation. The market is primarily driven by the urgent need to compress the lengthy timelines inherent in drug discovery and the imperative to decrease the massive capital expenditures associated with research and development. Validating this trend, the Pistoia Alliance reported in 2024 that 83% of life science professionals utilize generative AI in their research, highlighting the swift adoption of these technologies to boost operational efficiency and innovation capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.20 Billion
Market Size 2031USD 19.13 Billion
CAGR 2026-203128.75%
Fastest Growing SegmentDrug Discovery
Largest MarketNorth America

However, the market faces significant hurdles related to data quality and the intricacies of regulatory compliance regarding intellectual property. The accuracy of generative outputs relies heavily on unbiased, high-fidelity datasets, which are frequently fragmented or inconsistent within pharmaceutical enterprises. Additionally, the absence of harmonized global regulations generates uncertainty regarding data privacy and copyright issues, potentially impeding the scalable application of these tools in critical decision-making scenarios where safety and precision are non-negotiable.

Market Driver

The ability to accelerate drug discovery and development timelines through de novo molecular design serves as a major catalyst for the adoption of generative AI. While traditional discovery phases are notoriously protracted, generative models can now predict molecular interactions with exceptional precision, drastically reducing the number of experimental iterations needed to identify viable candidates. For instance, Google DeepMind announced in May 2024 that its AlphaFold 3 model achieved a 50% improvement in accuracy over conventional methods for predicting protein-ligand interactions. This significant leap in computational fidelity enables researchers to overcome earlier experimental bottlenecks, resulting in shorter development cycles and a faster transition from the laboratory to clinical trials for new therapeutics.

Furthermore, strategic alliances between established pharmaceutical corporations and specialized AI technology firms are driving market growth by combining biological expertise with computational power. Large pharmaceutical companies are increasingly outsourcing AI innovation through high-value partnerships to mitigate technical risks and access proprietary algorithmic platforms. A prime example occurred in January 2024, when Isomorphic Labs entered a collaboration with Eli Lilly valued at up to $1.7 billion to discover small molecule therapeutics for multiple targets. This trend of substantial capital investment is evident across the ecosystem, as seen with Xaira Therapeutics, which launched in 2024 with over $1 billion in committed capital to build an end-to-end AI platform for drug development, reflecting strong investor confidence in the industry's transformation.

Market Challenge

The absence of high-fidelity, unified data infrastructures constitutes a formidable barrier restricting the expansion of the Global Generative AI in Pharmaceutical Market. To accurately predict molecular properties or simulate biological responses, generative models require vast repositories of structured, unbiased data. Unfortunately, pharmaceutical data is often trapped in unstructured formats or fragmented across disparate legacy systems, rendering it unsuitable for immediate machine learning applications without extensive remediation. This disconnect between the technical requirements of AI architectures and the actual state of enterprise data forces organizations to divert substantial resources toward data cleansing rather than value-added innovation, directly negating the efficiency gains that drive market interest.

Consequently, this widespread lack of data readiness creates a bottleneck that stalls the scalable adoption of these technologies. According to the Pistoia Alliance in 2024, 52% of life science professionals identified low-quality and poorly curated datasets as the primary obstacle to AI implementation. When data integrity is compromised, the reliability of generative outputs diminishes, causing significant hesitation among stakeholders to integrate these tools into safety-critical workflows. As a result, the market struggles to realize the projected reductions in drug discovery timelines, effectively curbing the overall growth trajectory of the sector.

Market Trends

The integration of closed-loop "lab-in-the-loop" systems is revolutionizing drug discovery by linking generative AI models directly with automated robotic wet labs. In this workflow, AI algorithms formulate molecular hypotheses that are physically tested by robots, with the resulting data immediately retraining the model to refine subsequent predictions. This shift toward industrializing discovery through massive computational power is exemplified by recent infrastructure advancements; for example, Recursion announced in May 2024 the completion of its NVIDIA-powered BioHive-2 supercomputer, which is the fastest in the pharmaceutical industry and capable of processing data from over 2 million experiments per week to train proprietary foundation models.

Simultaneously, the emergence of synthetic data for clinical development is gaining traction as companies utilize generative AI to create high-fidelity "digital twins" of patients for use in synthetic control arms. This application addresses the challenge of patient scarcity in rare disease research by allowing trials to maintain statistical power with significantly fewer human participants. The market's commitment to this methodology is evident in recent capital allocations, such as Unlearn.AI's February 2024 announcement of raising $50 million in Series C funding to scale its TwinRCT solution, which leverages generative models to forecast patient health outcomes and effectively reduce the recruitment burden for clinical trials.

Key Market Players

  • AstraZeneca Plc
  • Nvidia
  • Baidu
  • Johnson & Johnson
  • Sanofi
  • Adaptyv Bio

Report Scope

In this report, the Global Generative AI in Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Generative AI in Pharmaceutical Market, By Drug Type

  • Small Molecule
  • Large Molecule

Generative AI in Pharmaceutical Market, By Application

  • Clinical Trial Research
  • Drug Discovery
  • Research And Development
  • Others

Generative AI in Pharmaceutical Market, By Technology

  • Deep Learning
  • Natural Language Processing
  • Querying Method
  • Context-aware Processing
  • Others

Generative AI in Pharmaceutical Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Generative AI in Pharmaceutical Market.

Available Customizations:

Global Generative AI in Pharmaceutical Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generative AI in Pharmaceutical Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Small Molecule, Large Molecule)
    • 5.2.2. By Application (Clinical Trial Research, Drug Discovery, Research And Development, Others)
    • 5.2.3. By Technology (Deep Learning, Natural Language Processing, Querying Method, Context-aware Processing, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Generative AI in Pharmaceutical Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Application
    • 6.2.3. By Technology
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Generative AI in Pharmaceutical Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Technology
    • 6.3.2. Canada Generative AI in Pharmaceutical Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Technology
    • 6.3.3. Mexico Generative AI in Pharmaceutical Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Technology

7. Europe Generative AI in Pharmaceutical Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Application
    • 7.2.3. By Technology
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Generative AI in Pharmaceutical Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Technology
    • 7.3.2. France Generative AI in Pharmaceutical Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Technology
    • 7.3.3. United Kingdom Generative AI in Pharmaceutical Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Technology
    • 7.3.4. Italy Generative AI in Pharmaceutical Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Technology
    • 7.3.5. Spain Generative AI in Pharmaceutical Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Technology

8. Asia Pacific Generative AI in Pharmaceutical Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Application
    • 8.2.3. By Technology
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Generative AI in Pharmaceutical Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Technology
    • 8.3.2. India Generative AI in Pharmaceutical Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Technology
    • 8.3.3. Japan Generative AI in Pharmaceutical Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Technology
    • 8.3.4. South Korea Generative AI in Pharmaceutical Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Technology
    • 8.3.5. Australia Generative AI in Pharmaceutical Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Technology

9. Middle East & Africa Generative AI in Pharmaceutical Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Application
    • 9.2.3. By Technology
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Generative AI in Pharmaceutical Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Technology
    • 9.3.2. UAE Generative AI in Pharmaceutical Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Technology
    • 9.3.3. South Africa Generative AI in Pharmaceutical Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Technology

10. South America Generative AI in Pharmaceutical Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Application
    • 10.2.3. By Technology
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Generative AI in Pharmaceutical Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Technology
    • 10.3.2. Colombia Generative AI in Pharmaceutical Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Technology
    • 10.3.3. Argentina Generative AI in Pharmaceutical Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Generative AI in Pharmaceutical Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Nvidia
  • 15.3. Baidu
  • 15.4. Johnson & Johnson
  • 15.5. Sanofi
  • 15.6. Adaptyv Bio

16. Strategic Recommendations

17. About Us & Disclaimer